drugset / Trial / NCT00004200

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00004200

Phase 2 Completed Pfizer
RandomizedTreatment

Summary

RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.

Timeline

Start
1999-10
Primary completion
2002-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject prinomastat Small molecule Oral
Background Temozolomide Small molecule Oral